NewAmsterdam Pharma Newsroom

Analysts Conflicted on These Healthcare Names: NewAmsterdam Pharma Company (NAMS) and Roche Holding AG (OtherRHHVF)

TipRanksNov 25 07:40 ET · Ratings

RBC Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $31

Moomoo NewsNov 21 21:32 ET · Ratings

RBC Capital Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)

TipRanksNov 21 20:45 ET · Ratings

NewAmsterdam Pharma Analyst Ratings

BenzingaNov 21 04:30 ET · Ratings

Express News | NewAmsterdam Pharma Company NV : Leerink Partners Raises Target Price to $45 From $42

ReutersNov 21 01:42 ET

Buy Rating for NewAmsterdam Pharma Amid Promising TANDEM Trial Results and Upcoming BROADWAY Trial Expectations

TipRanksNov 20 17:15 ET · Ratings

NewAmsterdam Pharma Down Over 15%, On Track for Largest Percent Decrease Since June 2023 -- Data Talk

Dow JonesNov 20 14:33 ET

NewAmsterdam Pharma's Anti-Bad Cholesterol Treatment Combination Meets Targets in Phase 3 Trial

MT NewswiresNov 20 09:33 ET

NewAmsterdam Pharma Phase 3 Drug Combo Study Hits Main Endpoints

WSJNov 20 07:35 ET

Express News | Trading Halt: Halt Status Updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

BenzingaNov 20 07:25 ET

Express News | NewAmsterdam Pharma Announces Positive Topline Data From Pivotal Phase 3 Tandem Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 Mg and Ezetimibe 10 Mg in Patients With Ascvd or Ascvd Risk Factors and/or Hefh

ReutersNov 20 07:00 ET

NewAmsterdam Pharma Announces Positive Topline Data From Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 Mg and Ezetimibe 10 Mg in Patients With ASCVD or ASCVD Risk Factors And/or HeFH

GlobeNewswireNov 20 07:00 ET

Express News | Trading Halt: Halted at 6:55:00 A.m. ET - Trading Halt: Halt News Pending

BenzingaNov 20 06:55 ET

Jefferies Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $45

Moomoo NewsNov 19 08:32 ET · Ratings

Piper Sandler Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $37

Moomoo NewsNov 19 07:33 ET · Ratings

NewAmsterdam Pharma Company (NAMS) Receives a Buy From Piper Sandler

TipRanksNov 19 06:47 ET · Ratings

NewAmsterdam Pharma Presents Additional Data From Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib In Patients With Heterozygous Familial Hypercholesterolemia At AHA Scientific Sessions 2024; Met Primary Endpoint With LDL-C Mean Reduction Versus...

BenzingaNov 18 15:21 ET

Express News | NewAmsterdam Pharma Presents Additional Data From Pivotal Phase 3 Brooklyn Clinical Trial Evaluating Obicetrapib in Patients With Heterozygous Familial Hypercholesterolemia at Aha Scientific Sessions 2024

ReutersNov 18 15:20 ET

Form 144 | NewAmsterdam Pharma(NAMS.US) Insider Proposes to Sell 38.81 Million in Common Stocks

SEC FILLINGS DISCLOSED/ Nov 13, $NEWAMSTERDAM PHARMA CO NV C/WTS (TO PUR COM)(NAMSW.US)$、$NewAmsterdam Pharma(NAMS.US)$ Insider NAP PoolCo B.V. intends to sell 1.55 million shares of its common

Moomoo NewsNov 13 16:29 ET

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Shares Could Be 46% Below Their Intrinsic Value Estimate

Yahoo FinanceNov 11 05:43 ET